Marcus Schmitt-Egenolf

• Real world evidence, Preventive medicine, Ethics, Psoriasis, Melanoma, Genodermatoses

• Coordinator, educationally awarded teachers network

• Head of the Swedish psoriasis register PsoReg

Contact

Works at

Professor, senior consultant (attending) physician at Department of Public Health and Clinical Medicine Units: Section of Medicine, Dermatology and Venereology

1A, målpunkt B41, enheten för medicin, Norrlands Universitetssjukhus Umeå universitet, by1a, B41, NUS, 901 85 Umeå

Marcus main interests are Real world evidence, Preventive medicine, Ethics, Psoriasis, Melanoma and Genodermatoses. He initiated the Swedish national psoriasis registry www.PsoReg.se and co-founded the international PsoNet register. Marcus is a distinguished teacher and co-coordinates the educationally awarded teachers network @ Umeå university. Marcus is a scientific advisor to several public authorities and other decision-makers and participates in national and international expert groups.

Bio:
Marcus studied medicine in Frankfurt, Vienna, Kiel & Edmonton. During his studies, he started his psoriasis research with a thesis on the immunogenetics of psoriasis under the guidance of Enno Christophers and Wolfram Sterry. The German research council (DFG) funded his postdoc at the laboratory of Georg Stingl in Vienna from 1993-95. Thereafter, he completed his specialist training at the Charité in Berlin. He was appointed associate professor of dermatology at the NTNU in Trondheim, Norway in 2000. Since 2002 he has been working at Umeå university, where he was appointed head of the division of dermatovenereology in 2012, full professor and distinguished teacher in 2014.

• Affiliated researcher
-Centre for Pharmacoepidemiology, Karolinska Institutet
www.safetyness.org
-Arctic Research Centre Arcum
• Associate Editor, British Journal of Dermatology
• Editorial board:
-BMC Dermatology
-Clinical Drug Investigation
-Journal of Clinical Medicine

Senior advisor:
• Swedish Board of Health and Welfare (SoS)
• Swedish Agency for Health Technology Assessment (SBU)
• Medical Products Agency (MPA)
• Swedish Dental and Pharmaceutical Benefits Agency (TLV)
• Swedish psoriasis patient organisation (PSO)

Coordinator:
• Master thesis (30 ECTS), medicine program, Umeå univ.
• Psoriasis research, the medical biobank Umeå

• Pubmed
• ResearchGate
• Publons
• LinkedIn

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

Journal of the European Academy of Dermatology and Venereology, John Wiley & Sons 2021, Vol. 35, (2) : 281-317

Nast, A.; Smith, C.; Spuls, P.I.; et al.

To what extent are topical tacrolimus or pimecrolimus associated with increased risk of skin cancer and lymphoma?: Longterm results from Joelle study

Pharmacoepidemiology and Drug Safety, John Wiley & Sons 2020, Vol. 29 : 568-569

Arana, Alejandro; Pottegard, Anton; Kuiper, Josephina G.; et al.

Anti-TNF treatment during pregnancy and birth outcomes: Apopulation-based study from Denmark, Finland, and Sweden

Pharmacoepidemiology and Drug Safety, Vol. 29, (3) : 316-327

Broms, Gabriella; Kieler, Helle; Ekbom, Anders; et al.

Paediatric infections in the first 3 years of life after maternal anti-TNF treatment during pregnancy

Alimentary Pharmacology and Therapeutics, John Wiley & Sons 2020, Vol. 52, (5) : 843-854

Bröms, Gabriella; Kieler, Helle; Ekbom, Anders; et al.

Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study

JAMA dermatology, American Medical Association 2020, Vol. 156, (7) : 795-804

Geale, Kirk; Henriksson, Martin; Jokinen, Jussi; et al.

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations

Journal of the European Academy of Dermatology and Venereology, John Wiley & Sons 2020, Vol. 34, (11) : 2461-2498

Nast, A.; Smith, C.; Spuls, P. I.; et al.

Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health-related quality of life improvements and implications for treatment goals

British Journal of Dermatology, Wiley-Blackwell 2020, Vol. 182, (4) : 965-973

Norlin, J. M.; Nilsson, K.; Persson, U.; et al.

Complete skin clearance and beyond

British Journal of Dermatology

Schmitt-Egenolf, Marcus

British Journal of Dermatology, Wiley-Blackwell 2020, Vol. 182, (2) : 506-508

Tufvesson Stiller, Helena; Mikiver, R.; Uppugunduri, S.; et al.

Infant Infections after Maternal Anti-TNF Treatment in Pregnancy

Pharmacoepidemiology and Drug Safety, Wiley 2019, Vol. 28 : 10-10

Broms, Gabriella; Kieler, Helle; Ekbom, Anders; et al.

Case validation of cutaneous lymphoma to minimize protopathic bias

Pharmacoepidemiology and Drug Safety, Wiley 2019, Vol. 28, (S2) : 315-315

Gutierrez, Lia; Booth, Helen; Dedman, Daniel; et al.

Tnf inhibitor treatment during pregnancy and risk of preterm birth

Pharmacoepidemiology and Drug Safety, John Wiley & Sons 2018, Vol. 27 : 30-31

Bröms, Gabriella; Kieler, Helle; Ekbom, Anders; et al.

Sustained Psoriasis Area and Severity Index, DermatologyLife Quality Index and EuroQol-5D response of biologicaltreatment in psoriasis: 10 years of real-world data in theSwedish National Psoriasis Register

British Journal of Dermatology, Hoboken: John Wiley & Sons 2018, Vol. 178, (1) : 245-252

Hjalte, F.; Steen Carlsson, K.; Schmitt-Egenolf, Marcus

What can we learn from 'dropouts' in clinical trials?

British Journal of Dermatology, John Wiley & Sons 2018, Vol. 178, (2) : 318-319

Schmitt-Egenolf, Marcus

Regional Differences in the Prescription of Biologics for Psoriasis in Sweden: a Register-Based Study of 4168 Patients

BioDrugs, Vol. 31, (1) : 75-82

Calara, Paul S; Althin, Rikard; Carlsson, Katarina Steen; et al.

How is disease severity associated with quality of life in psoriasis patients?: Evidence from a longitudinal population-based study in Sweden

Health and Quality of Life Outcomes, Vol. 15, (1)

Geale, Kirk; Henriksson, Martin; Schmitt-Egenolf, Marcus

Severity of psoriasis differs between men and women: a registry based study of the clinical outcome measure Psoriasis Area and Severity Index (PASI) in 5438 patients

American Journal of Clinical Dermatology, Vol. 18 : 583-590

Hägg, David; Sundström, Anders; Eriksson, Marie; et al.

Real-world outcomes in 2,646 psoriasis patients: one in five has PASI ≥ 10 and/or DLQI ≥ 10 under ongoing systemic therapy

Journal of dermatological treatment (Print), Vol. 28, (6) : 500-504

Norlin, J. M.; Calara, P. S.; Persson, U.; et al.

Healthcare Provider Type and Switch to Biologics in Psoriasis: Evidence from Real-World Practice

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, Vol. 30, (2) : 145-151

Calara, Paul S.; Norlin, Jenny M.; Althin, Rikard; et al.

Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription biologics

British Journal of Dermatology, Vol. 174, (3) : 579-587

Gaele, Kirk; Henriksson, Martin; Schmitt-Egenolf, Marcus

Psoriasis Patients New to Specialist Care in Sweden 2007-2009: A Two-Year Follow-Up of Treatment Allocation

Pharmacoepidemiology and Drug Safety, Wiley-Blackwell 2016, Vol. 25 : 4-5

Hägg, David; Eriksson, Marie; Schmitt-Egenolf, Marcus; et al.

Periodontal Ehlers-Danlos Syndrome Is Caused by Mutations in C1R and C1S, which Encode Subcomponents C1r and C1s of Complement

American Journal of Human Genetics, Cell Press 2016, Vol. 99, (5) : 1005-1014

Kapferer-Seebacher, Ines; Pepin, Melanie; Werner, Roland; et al.

Physical activity and lifestyle improvement in the management of psoriasis

British Journal of Dermatology, Vol. 175, (3) : 452-453

Schmitt-Egenolf, Marcus

The Relationship Between Disease Severity and Quality of Life In Patients With Moderate to Severe Psoriasis

Value in Health, Vol. 18, (7) : A675-A675

Geale, Kirk; Henriksson, M.; Schmitt-Egenolf, Marcus

Real-world outcome analysis of continuously and intermittently treated patients with moderate to severe psoriasis after switching to a biologic agent

Dermatology, S. Karger 2015, Vol. 230, (4) : 347-353

Hjalte, Frida; Steen Carlsson, Katarina; Schmitt-Egenolf, Marcus

Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI)

Journal of the European Academy of Dermatology and Venereology, John Wiley & Sons 2015, Vol. 29, (3) : 452-456

Hägg, David; Sundström, A; Eriksson, Marie; et al.

Register-Based Evaluation of Relative Effectiveness of New Therapies: Biologics Versus Conventional Agents in Treatment of Psoriasis in Sweden

BioDrugs, Vol. 29, (6) : 389-398

Norlin, Jenny M.; Steen Carlsson, Katarina; Persson, Ulf; et al.

Resource use in patients with psoriasis after the introduction of biologics in Sweden

Acta Dermato-Venereologica, Vol. 95, (2) : 156-161

Norlin, Jenny M.; Steen Carlsson, Katarina; Persson, Ulf; et al.

Hair shaft structures in EDAR induced ectodermal dysplasia

BMC Medical Genetics, BioMed Central 2015, Vol. 16

Stecksén-Blicks, Christina; Falk Kieri, Catharina; Schmitt-Egenolf, Marcus; et al.

EDAR-induced hypohidrotic ectodermal dysplasia: a clinical study on signs and symptoms in individuals with a heterozygous c.1072C > T mutation

BMC Medical Genetics, BioMed Central 2014, Vol. 15 : 57-

Falk Kieri, Catarina; Bergendal, Birgitta; Lind, Lisbet K; et al.

Health care delay in malignant melanoma: various pathways to diagnosis and treatment

Dermatology Research and Practice, Hindawi Publishing Corporation 2014 : 294287-

Hajdarevic, Senada; Hörnsten, Åsa; Sundbom, Elisabet; et al.

Registerstudier mäter effektivitet av läkemedel i klinisk praxis: Exemplet PsoReg – omfördelning av systemisk terapi kan ge ökad effektivitet

Läkartidningen, Vol. 111, (24) : 1061-3

Norlin, Jenny; Schmitt-Egenolf, Marcus; Steen Carlsson, Katarina; et al.

Coping styles in decision making among men and women diagnosed with malignant melanoma

Journal of Health Psychology, Sage Publications 2013, Vol. 18, (11) : 1445-1455

Hajdarevic, Senada; Schmitt-Egenolf, Marcus; Sundbom, Elisabet; et al.

The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men

PLoS ONE, Public library of science 2013, Vol. 8, (5) : e63619-

Hägg, David; Eriksson, Marie; Sundström, Anders; et al.

Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients

British Journal of Dermatology, Wiley-Blackwell 2012, Vol. 166, (4) : 797-802

Norlin, Jenny M; Steen Carlsson, K; Persson, U; et al.

Switch to biological agent in psoriasis significantly improved clinical and patient-reported outcomes in real-world practice

Dermatology, S. Karger 2012, Vol. 225, (4) : 326-332

Norlin, Jenny M; Steen Carlsson, Katarina; Persson, Ulf; et al.

Challenges for synthesising data in a network of registries for systemic Psoriasis therapies

Dermatology, S. Karger 2012, Vol. 224, (3) : 236-243

Ormerod, AD; Augustin, M; Baker, C; et al.

Malignant melanoma: gender patterns in care seeking for suspect marks

Journal of Clinical Nursing, Wiley-Blackwell 2011, Vol. 20, (17-18) : 2676-2684

Hajdarevic, Senada; Schmitt-Egenolf, Marcus; Brulin, Christine; et al.

Patients' decision making in seeking care for suspected malignant melanoma

Journal of Nursing and Healthcare of Chronic Illness, Wiley-Blackwell 2010, Vol. 2, (2) : 164-173

Hajdarevic, Senada; Hörnsten, Åsa; Sundbom, Elisabet; et al.

How dermatologists can evaluate systemic psoriasis treatments

Forum for nordic dermato-venereology, Vol. 14, (2) : 38-40

Schmitt-Egenolf, Marcus

Switching biologicals: switching TNFalpha antagonists in psoriasis treatment

Dermatology, S. Karger 2008, Vol. 216, (4) : 281-282

Schmitt-Egenolf, Marcus

PsoReg: the Swedish registry for systemic psoriasis treatment. The registry's design and objectives.

Dermatology, S. Karger 2007, Vol. 214, (2) : 112-117

Schmitt-Egenolf, Marcus

EDAR mutation in autosomal dominant hypohidrotic ectodermal dysplasia in two Swedish families

BMC Medical Genetics, BioMed Central 2006, Vol. 7 : 80-

Lind, Lisbet K; Stecksén-Blicks, Christina; Lejon, Kristina; et al.

Psoriasis therapy in real life: the need for registries

Dermatology, S. Karger 2006, Vol. 213, (4) : 327-330

Schmitt-Egenolf, Marcus

Pso-Reg: the quality register for systemic psoriasis treatment

Forum for Nordic dermato-venereology, Nordic dermatological association 2004, Vol. 9, (4) : 94-97

Schmitt-Egenolf, Marcus

Interleukin-10 promoter polymorphism IL10.G and familial early onset psoriasis

British Journal of Dermatology, John Wiley & Sons 2003, Vol. 149, (2) : 381-385

Hensen, P; Asadullah, K; Windemuth, C; et al.

Association scan of the novel psoriasis susceptibility region on chromosome 19: evidence for both susceptible and protective loci

Experimental dermatology, John Wiley & Sons 2003, Vol. 12, (4) : 490-496

Hensen, P; Windemuth, C; Hüffmeier, U; et al.

Comparative association analysis reveals that corneodesmosin is more closely associated with psoriasis than HLA-Cw*0602-B*5701 in German families

Tissue Antigens, John Wiley & Sons 2001, Vol. 57, (5) : 440-446

Schmitt-Egenolf, Marcus; Windemuth, C; Hennies, HC; et al.

Genomewide scan in german families reveals evidence for a novel psoriasis-susceptibility locus on chromosome 19p13

American Journal of Human Genetics, Elsevier 2000, Vol. 67, (4) : 1020-1024

Lee, YA; Rüschendorf, F; Windemuth, C; et al.

PERB11 (MIC): a polymorphic MHC gene is expressed in skin and single nucleotide polymorphisms are associated with psoriasis.

Clinical and Experimental Immunology, John Wiley & Sons 2000, Vol. 119, (3) : 553-558

Tay, GK; Hui, J; Gaudieri, S; et al.

View publications in DiVA

Research projects

6 October 2010 until 31 May 2013

Melanoma, a new approach to decrease delay of diagnosis and treatment

Published: 04 Jun, 2020

Psoriasis patients’ mental health is more than skin-deep